Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
This commentary examines the consequences of a medical student’s dishonesty during clinical rounds when she lacked the lab results the attending physician asked her for.
Parents’ right to choose the culture of their children and a child’s right to an open future outweigh the right of the Deaf to perpetuate their culture by disallowing government funding of cochlear implant research to restore hearing.
A first-person account of the development and implementation of a professionalism curriculum at New York University School of Medicine that uses online student portfolios as its principal means for evaluating professional development.
A physicians urges practitioners to use cost-effective alternatives to dispensing samples to patients who cannot afford to pay for their prescriptions.
A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
A physician argues that pharmaceutical industry support for residency programs creates a conflict of interest and compromises the educational integrity of the programs.
A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.